Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 33Sarcoma 2Genitourinary 2CNS 1

Conditions

Carcinoma, Renal Cell 11Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Kidney Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Neoplasms 1

Interventions

pembrolizumab 75Nivolumab 46Cyclophosphamide 25aldesleukin 23fludarabine 16atezolizumab 15Ipilimumab 15Interleukin-2 14Radiosurgery 13Paclitaxel 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Carboplatin 11fludarabine phosphate 9Docetaxel 9durvalumab 8Cisplatin 8cemiplimab 7Bevacizumab 7Radiotherapy 6Gemcitabine 6Biopsy 6spartalizumab 5avelumab 5Pemetrexed 5Oxaliplatin 5Immune Checkpoint Inhibitors 5Filgrastim 5Cryosurgery 5Blood Specimen Collection 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Introns × Genitourinary × Clear all
NCT00629200 2018-11-15

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT00217542 2013-05-03

Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡